Also listed under Hemostatic Disorders, Lymphoproliferative Disorders, Paraproteinemias
87 trials changed in the last 30 days: 3 stopped, 35 with notable changes, 49 with minor changes only.
Trial terminated
Sponsor's reason: Loss of further funding
Also in this update: Primary completion date changed from estimate of Mar 31, 2027 to Aug 28, 2026; Final enrollment: 21 participants (planned 42)
Washington University School of MedicineEarly Phase 1 NCT06636175 Registry history of NCT06636175 on ClinicalTrials.gov (opens the registry)
Updated
Withdrawn before enrolling
Sponsor's reason: Due to barriers in anticipated accrual
Cristiana Costa Chase, DOPhase 2 NCT05874193 Registry history of NCT05874193 on ClinicalTrials.gov (opens the registry)
Updated
Withdrawn before enrolling
Sponsor's reason: The study was revised into two separate protocols to separate treatments. We will submit as separate studies.
Baylor College of MedicinePhase 1 NCT07297160 Registry history of NCT07297160 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Mar 13, 2029 to Sep 27, 2029
And 1 more change in the last 30 days
CSL BehringPhase 3 NCT07648264 Registry history of NCT07648264 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Sep 2026 to Sep 2027
Memorial Sloan Kettering Cancer CenterPhase 1 NCT02909036 Registry history of NCT02909036 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Jul 1, 2029 to Sep 2032
SWOG Cancer Research NetworkPhase 3 NCT04071457 Registry history of NCT04071457 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2027
National Cancer Institute (NCI)Phase 2 NCT02465060 Registry history of NCT02465060 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Jun 2026 to Jan 2027
Also in this update: Study completion pushed from Jan 2027 to May 2027
Abramson Cancer Center at Penn MedicinePhase 2 NCT05932680 Registry history of NCT05932680 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Jul 2026 to Jul 2028
Bnai Zion Medical CenterNot applicable NCT06515249 Registry history of NCT06515249 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Jan 1, 2026 to Sep 1, 2027
Fondazione EMN Italy OnlusPhase 3 NCT04096066 Registry history of NCT04096066 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Apr 2026 to Jun 2027
Also in this update: Enrollment closed, study ongoing; Trial sites reduced: 29 → 22 locations
University Hospital, LillePhase 2 NCT05572229 Registry history of NCT05572229 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Oct 21, 2026 to Jul 29, 2027
Also in this update: Study completion moved earlier from Sep 1, 2029 to Jul 29, 2027
Roswell Park Cancer InstitutePhase 2 NCT04876248 Registry history of NCT04876248 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Aug 2026 to Aug 2027
Memorial Sloan Kettering Cancer CenterPhase 2 NCT02538198 Registry history of NCT02538198 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Dec 2027 to Sep 2028
Also in this update: Enrollment closed, study ongoing
University of Alabama at BirminghamPhase 2 NCT05231629 Registry history of NCT05231629 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Feb 2027 to Feb 2028
Also in this update: Recruitment resumed after suspension
Hackensack Meridian HealthPhase 2 NCT04661137 Registry history of NCT04661137 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Jul 31, 2026 to Sep 8, 2027
University of RochesterPhase 2 NCT04635189 Registry history of NCT04635189 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Sep 2026 to Sep 2027
Memorial Sloan Kettering Cancer CenterNot applicable NCT06055894 Registry history of NCT06055894 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Sep 2026 to Sep 2027
Also in this update: Study completion pushed from Mar 2027 to Mar 2028
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEarly Phase 1 NCT06398457 Registry history of NCT06398457 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Sep 2026 to Aug 2027
Hackensack Meridian HealthPhase 1 NCT03909412 Registry history of NCT03909412 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Aug 1, 2026 to Jan 31, 2027
Also in this update: Study completion pushed from Sep 1, 2026 to Mar 1, 2027
Robert Flavell, MD, PhDPhase 1 NCT05892393 Registry history of NCT05892393 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Janssen Research & Development, LLCPhase 2 NCT07266441 Registry history of NCT07266441 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Primary completion date changed from estimate of Oct 30, 2025 to May 5, 2025
Centre Hospitalier Universitaire de Saint EtienneNot applicable NCT05259553 Registry history of NCT05259553 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Final enrollment: 20 participants (planned 17)
Larysa SanchezPhase 2 NCT04052880 Registry history of NCT04052880 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Susan BalPhase 1 NCT07333261 Registry history of NCT07333261 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
M.D. Anderson Cancer CenterPhase 2 NCT05336383 Registry history of NCT05336383 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Jul 18, 2026 to Sep 28, 2026
Also in this update: Trial sites reduced: 207 → 204 locations
Bristol-Myers SquibbPhase 3 NCT05552976 Registry history of NCT05552976 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Primary completion date changed from estimate of Feb 2027 to Oct 6, 2026
Memorial Sloan Kettering Cancer CenterPhase 1 NCT03070327 Registry history of NCT03070327 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Aug 31, 2026 to Dec 31, 2026
Northside Hospital, Inc.Phase 2 NCT05909059 Registry history of NCT05909059 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Primary completion date changed from estimate of Oct 7, 2026 to Aug 28, 2026
University Hospital, LillePhase 3 NCT03993912 Registry history of NCT03993912 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Aug 1, 2028 to Dec 31, 2028
Also in this update: Study completion pushed from Dec 1, 2028 to Dec 31, 2030
The Affiliated People's Hospital of Ningbo UniversityPhase 2/3 NCT07732712 Registry history of NCT07732712 on ClinicalTrials.gov (opens the registry)
Updated
Reclassified as completed (was terminated)
Shanghai Changzheng HospitalPhase 1 NCT05376345 Registry history of NCT05376345 on ClinicalTrials.gov (opens the registry)
Updated
Sponsor refiled this as recruiting (was completed)
British Columbia Cancer AgencyNot specified NCT06224309 Registry history of NCT06224309 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Study completion date changed from estimate of Dec 19, 2026 to Jul 24, 2026
University of WashingtonNot applicable NCT03389347 Registry history of NCT03389347 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 75 → 93 locations
Hoffmann-La RochePhase 3 NCT07555938 Registry history of NCT07555938 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 56 → 65 locations
TakedaPhase 3 NCT06980480 Registry history of NCT06980480 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Sep 15, 2026 to Feb 15, 2027
Massachusetts General HospitalPhase 1 NCT02886065 Registry history of NCT02886065 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Aug 31, 2026 to Dec 31, 2026
Washington University School of MedicineNot applicable NCT07226934 Registry history of NCT07226934 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment increased: 166 → 190 participants
ModernaTX, Inc.Phase 1/2 NCT07116616 Registry history of NCT07116616 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 28 → 39 locations
And 1 more change in the last 30 days
Regeneron PharmaceuticalsPhase 3 NCT07222761 Registry history of NCT07222761 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Dec 18, 2026 to May 15, 2027
Mayo ClinicPhase 2 NCT07285044 Registry history of NCT07285044 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment increased: 240 → 276 participants
And 2 more changes in the last 30 days
Janssen Research & Development, LLCPhase 1 NCT06768489 Registry history of NCT06768489 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Mar 2027 to Sep 2027
Also in this update: Enrollment increased: 32 → 36 participants; Study completion pushed from Sep 2027 to Mar 2028
Centre Hospitalier Universitaire de Saint EtienneNot applicable NCT06474182 Registry history of NCT06474182 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 151 → 173 locations
Janssen Research & Development, LLCPhase 3 NCT07518186 Registry history of NCT07518186 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 139 → 160 locations
PfizerPhase 3 NCT05623020 Registry history of NCT05623020 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 14 → 19 locations
Regeneron PharmaceuticalsPhase 3 NCT07393282 Registry history of NCT07393282 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 144 → 150 locations
Janssen Research & Development, LLCPhase 3 NCT07258511 Registry history of NCT07258511 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 9 → 38 locations
Janssen Research & Development, LLCPhase 2 NCT07589634 Registry history of NCT07589634 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 17 → 20 locations
Janssen Research & Development, LLCPhase 2 NCT07149857 Registry history of NCT07149857 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 81 → 84 locations
Shanghai Henlius BiotechPhase 1 NCT07477587 Registry history of NCT07477587 on ClinicalTrials.gov (opens the registry)
Updated
Start date pushed from Oct 1, 2026 to Oct 30, 2026
Hoffmann-La RochePhase 2 NCT07825064 Registry history of NCT07825064 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 64 → 69 locations
Intergroupe Francophone du MyelomePhase 3 NCT06918002 Registry history of NCT06918002 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 7 → 12 locations
Multiple Myeloma Research ConsortiumPhase 2 NCT07053436 Registry history of NCT07053436 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 14 → 17 locations
And 1 more change in the last 30 days
National Cancer Institute (NCI)Phase 2 NCT06948084 Registry history of NCT06948084 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 2 → 7 locations
National Cancer Institute (NCI)Phase 2 NCT07605416 Registry history of NCT07605416 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion date changed from estimate of Dec 31, 2026 to Oct 15, 2021
National Cancer Institute (NCI)Phase 2 NCT06400225 Registry history of NCT06400225 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 1 → 4 locations
City of Hope Medical CenterPhase 2 NCT06052826 Registry history of NCT06052826 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion moved earlier from Sep 15, 2025 to Aug 1, 2025
Janssen Research & Development, LLCPhase 3 NCT05083169 Registry history of NCT05083169 on ClinicalTrials.gov (opens the registry)
Updated
Study completion pushed from Apr 7, 2027 to Dec 31, 2027
Janssen Research & Development, LLCPhase 1 NCT05050097 Registry history of NCT05050097 on ClinicalTrials.gov (opens the registry)
Updated
Study completion pushed from May 3, 2027 to Dec 31, 2027
Janssen Research & Development, LLCPhase 1 NCT05338775 Registry history of NCT05338775 on ClinicalTrials.gov (opens the registry)
Updated
Study completion pushed from Apr 7, 2027 to Dec 31, 2027
Janssen Research & Development, LLCPhase 1 NCT04108195 Registry history of NCT04108195 on ClinicalTrials.gov (opens the registry)
Updated
Study completion pushed from Sep 30, 2026 to Sep 23, 2027
Also in this update: Primary completion date changed from estimate of Sep 30, 2026 to Apr 15, 2026; Final enrollment: 58 participants (planned 70)
National Cancer Institute (NCI)Phase 2 NCT06169215 Registry history of NCT06169215 on ClinicalTrials.gov (opens the registry)
Updated
Study completion pushed from Jun 2026 to Jun 2027
Memorial Sloan Kettering Cancer CenterPhase 3 NCT04459416 Registry history of NCT04459416 on ClinicalTrials.gov (opens the registry)
Updated
Interventions modified
Also in this update: Trial arms changed: 13 → 12
American Society of Clinical OncologyPhase 2 NCT02693535 Registry history of NCT02693535 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion moved earlier from Dec 1, 2026 to Nov 1, 2026
Washington University School of MedicineNot applicable NCT06910670 Registry history of NCT06910670 on ClinicalTrials.gov (opens the registry)
Updated
Study completion pushed from Jun 2026 to Jun 2027
Memorial Sloan Kettering Cancer CenterNot applicable NCT04920084 Registry history of NCT04920084 on ClinicalTrials.gov (opens the registry)
Updated
Registry marked status Unknown (sponsor has not verified the record since Aug 2021); last known: Not Yet Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 1/2 NCT05055791 Registry history of NCT05055791 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Hospital General de MexicoNot specified NCT06284395 Registry history of NCT06284395 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
Joseph TuscanoPhase 1/2 NCT02542657 Registry history of NCT02542657 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1 NCT05913804 Registry history of NCT05913804 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-01 | NCT07851493 Exercise Phenotyping Prior to Chemotherapy in Newly Diagnosed Multiple Myeloma… | Technical University of Munich new | |
| 2026-09-16 | NCT07823426 Cervical Spinal Cord Signal Abnormalities in Patients With Cervical Radicular Pain | Ankara City Hospital Bilkent new | |
| 2026-09-10 | NCT07814170 A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In… | University of West Attica new | |
| 2026-09-09 | NCT07809594 CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma | Qi Junyuan new | Phase 1 |
| 2026-09-03 | NCT07802717 A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169)… | Vyriad, Inc. new | Phase 1 |
| 2026-08-25 | NCT07783607 MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma | University of Vermont Medical Center new | |
| 2026-08-24 | NCT07782944 CD38 Targeted -PET/ CT for Multiple Myeloma | Guilin Medical University, China new | |
| 2026-08-20 | NCT07776964 Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments… | University of Minnesota new | |
| 2026-08-19 | NCT07774988 Individualized Education for Bortezomib-Related Symptom Management in Multiple Myeloma | Can Lafci new | |
| 2026-08-18 | NCT07771803 A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia… | Roger Strair new | Early Phase 1 |
| Early Phase 1 | 49 | |
| Phase 1 | 166 | |
| Phase 1/2 | 113 | |
| Phase 2 | 284 | |
| Phase 2/3 | 13 | |
| Phase 3 | 110 | |
| Phase 4 | 18 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT05201781 | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | Janssen Research & Development, LLC | Recruiting | 2026-09-25 |
| NCT07609940 | Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of… | Regeneron Pharmaceuticals | Recruiting | 2026-09-25 |
| NCT07101445 | Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the… | Emory University | Recruiting | 2026-07-23 |
| NCT07094048 | Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager | CHU de Quebec-Universite Laval | Recruiting | 2026-07-22 |
| NCT06057402 | Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) | Pfizer | Recruiting | 2026-07-01 |
| NCT05722405 | Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of… | Second Affiliated Hospital, Zhejiang University, School of Medicine | Recruiting | 2026-01-05 |
| NCT06251076 | Plan Development for Giving Teclistamab in the Outpatient Setting | University Health Network, Toronto | Recruiting | 2025-12-10 |
| NCT07025005 | Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib… | Tanta University | Recruiting | 2025-11-04 |
| NCT06409702 | Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease… | The First Affiliated Hospital of Soochow University | Recruiting | 2025-06-12 |
| NCT07030517 | A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and… | Johnson & Johnson Private Limited | Active, Not Recruiting | 2026-09-25 |
| NCT07709884 | A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly… | The First Affiliated Hospital of Soochow University | Not Yet Recruiting | 2026-07-17 |
| NCT07191379 | Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma | Odense University Hospital | Not Yet Recruiting | 2026-06-05 |
| NCT07474961 | BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. | Anne Louise Tølbøll Sørensen | Not Yet Recruiting | 2026-03-16 |
| NCT07334535 | Isa-VRD in TIE HRMM | Peking Union Medical College Hospital | Not Yet Recruiting | 2026-01-13 |
| NCT03829371 | STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION… | University of Turin, Italy | Active, Not Recruiting | 2025-12-03 |
| NCT07154537 | Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM) | National Taiwan University Hospital | Active, Not Recruiting | 2025-09-04 |
| NCT05944783 | Bioequivalence Studies of Dasatinib 100 Mg | Centro de Atencion e Investigacion Medica | Not Yet Recruiting | 2025-02-12 |
| NCT05429515 | Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury | Peking Union Medical College Hospital | Not Yet Recruiting | 2022-06-23 |
| Phase 3 | ||||
| NCT06182774 | Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older… | Canadian Cancer Trials Group | Recruiting | 2026-10-14 |
| NCT07648264 | Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to… | CSL Behring | Recruiting | 2026-10-14 |
| NCT06980480 | A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in… | Takeda | Recruiting | 2026-10-13 |
| NCT07555938 | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… | Hoffmann-La Roche | Recruiting | 2026-10-13 |
| NCT07624513 | D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation &… | Dana-Farber Cancer Institute | Recruiting | 2026-10-09 |
| NCT07222761 | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination… | Regeneron Pharmaceuticals | Recruiting | 2026-10-08 |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone… | European Myeloma Network B.V. | Recruiting | 2026-10-07 |
National Cancer Institute (NCI) (52) · Institute of Hematology & Blood Diseases Hospital, China (38) · Memorial Sloan Kettering Cancer Center (35) · Janssen Research & Development, LLC (29) · M.D. Anderson Cancer Center (21) · GlaxoSmithKline (20) · AbbVie (17) · Mayo Clinic (15) · Massachusetts General Hospital (13) · PETHEMA Foundation (12)